Last reviewed · How we verify
NCT04484220
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
NA trial testing Ellipsys Vascular Access System in Renal Disease, End Stage in 142 participants. Completed in 31 March 2025.
31 March 2025
Quick facts
| Lead sponsor | Medtronic Endovascular |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 142 |
| Start date | 13 April 2021 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 12 locations across United States |
Drugs / interventions tested
- Ellipsys Vascular Access System
Conditions studied
- Renal Disease, End Stage — all drugs for Renal Disease, End Stage →
- Kidney Disease, End-Stage — all drugs for Kidney Disease, End-Stage →
- AV Fistula — all drugs for AV Fistula →
- Fistulas Arteriovenous — all drugs for Fistulas Arteriovenous →
Sponsor
Medtronic Endovascular — full company profile →
Who can join
Adults 18 to 80, any sex, with Renal Disease, End Stage or Kidney Disease, End-Stage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed clinical study is a prospective, non-randomized, multi-center, single-arm, observational, post-market surveillance (PS) study of the Ellipsys Vascular Access System in subjects eligible for arteriovenous (AV) fistula.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04484220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Disease, End Stage
Currently open trials in the same condition.
- NCT04347629 — Improving Medical Decision Making for Older Patients With End Stage Renal Disease · NA · active not recruiting
Other Medtronic Endovascular trials
Trials by the same sponsor.
- NCT03820947 — VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial · NA · terminated
- NCT04494035 — AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System · NA · terminated
- NCT04120610 — FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia · terminated
- NCT03869645 — CAPERE Thrombectomy System Post-Market Clinical Follow Up Study · terminated
- NCT03038438 — ABRE Clinical Study of the Abre Venous Self-expanding Stent System · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04484220 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medtronic Endovascular
- Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04484220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing